title: Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
authors.affiliation: Department of Internal Medicine - Hematooncology, Masaryk University and University Hospital Brno, Czech Republic. petr.szturz@fnbrno.cz
authors.forename: Petr
authors.initials: P
authors.lastname: Szturz
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Adam
authors.forename: Mária
authors.initials: M
authors.lastname: Klincová
authors.forename: Josef
authors.initials: J
authors.lastname: Feit
authors.forename: Marta
authors.initials: M
authors.lastname: Krejčí
authors.forename: Luděk
authors.initials: L
authors.lastname: Pour
authors.forename: Lenka
authors.initials: L
authors.lastname: Zahradová
authors.forename: Vladimír
authors.initials: V
authors.lastname: Vašků
authors.forename: Roman
authors.initials: R
authors.lastname: Hájek
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D010392:Pemphigus / Q000150:complications* / Q000276:immunology; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D001897:Boronic Acids; D007070:Immunoglobulin A; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide